Is It Too Late to Buy Johnson & Johnson After Its Blowout Earnings Report?

Johnson & Johnson delivered strong earnings with revenue growth of 6% to $25 billion and raised full-year guidance to $101.1 billion. Key drugs like Darzalex (up 18%) and Tremfya (up 72%) offset Stelara declines. While the stock has gained 22% this year and trades near valuation highs, the company's broad portfolio of 28+ blockbuster products and 50+ years of dividend increases make it attractive for long-term and dividend-focused investors, though value investors may wait for a better entry point.